论文部分内容阅读
通过ＦＡＢ分型，ＭｃＡｂ免疫分型及分子生物学，如ＤＮＡ序列分析研究免疫球蛋白及ＴｃＲ的基因重排，研究白血病的发生发展规律更确切地进行白血病分类。结果３４例小儿急性白血病中，ＦＡＢ分型与免疫分型符合３０例，不符合４例，分子生物学均支持后者分型。临床上按形态分型设计方案，治疗效果均不良。分子生物学研究提示ＩｇＨ、ＩｇＫ基因重排具有很高的Ｂ细胞系特异桂，ＴｃＲδ基因的重排不显示严格的细胞特异性。文中对１例急性未分化白血病发病初期进行基因序列分析，治疗二年零二个月后再重复检查，结果阴性，成功地探测白血病治疗后残留白血病细胞的存在与否。这就克服了过去盲目延长缓解期化疗期限，为个体化方案的设计起重大作用。
Through FAB typing, McAb immunophenotyping and molecular biology, such as DNA sequence analysis of immunoglobulin and TcR gene rearrangement, the study of the occurrence and development of leukemia more accurate classification of leukemia. Results In 34 cases of pediatric acute leukemia, FAB typing and immunophenotyping coincided with 30 cases, which did not conform to 4 cases. Both of them were supported by molecular biology. According to the morphological typing clinical design program, the treatment effect is poor. Molecular biology studies suggest IgH, IgK gene rearrangement has a high B cell line specific Gui, TcRδ gene rearrangement does not show strict cell specificity. In the present study, the gene sequence analysis was performed in the early stage of one case of acute undifferentiated leukemia. After two years and two months of treatment, the results were repeated and the results were negative. The presence of residual leukemia cells after leukemia treatment was successfully detected. This overcomes the blind extension of the past period of remission chemotherapy, the design of individual programs play a significant role.